Champions Oncology, Inc. (CSBR) Research
Champions Oncology, Inc. is dedicated to developing and commercializing cutting-edge technological products and services designed to personalize cancer treatment and streamline the development of oncology drugs across the United States. At the heart of its offerings is the Tumorgraft Technology Platform, an innovative approach that facilitates individualized cancer care by implanting human tumors into immune-deficient mice. Utilizing this proprietary platform, the company not only delivers personalized cancer solutions directly but also provides Translational Oncology Solutions, supporting pharmaceutical and biotechnology companies through their drug development lifecycle. Additionally, Champions Oncology offers Lumin Bioinformatics, a comprehensive software platform and data tool filled with insights from research services and clinical studies, accessible through annual subscriptions. The company distributes its offerings through various channels, including online platforms, word-of-mouth referrals, and a dedicated sales team, reaching both patients and healthcare professionals. Established in 1985, Champions Oncology, Inc. is based in Hackensack, New Jersey, and was formerly known as Champions Biotechnology, Inc. until its name change in April 2011.
Market snapshot
- Symbol
- CSBR
- Price
- $6.32
- Day change
- -7.33%
- Market cap
- $87.8M
- P/E ratio
- -38.96x
- 52-week range
- 5.5-9.63
- Sector
- Healthcare
- Industry
- Biotechnology
- Next earnings
- in 26 days
- Analyst price target
- $12.00
Peer companies
Recent insider activity
- Brainin Robert Lawrence — A-Award (100000 shares) on 2025-07-16
- Brainin Robert Lawrence — A-Award (100000 shares) on 2025-07-16
- Brainin Robert Lawrence — A-Award (150000 shares) on 2025-07-16
- Brainin Robert Lawrence — A-Award (62500 shares) on 2025-07-16
- Brainin Robert Lawrence — A-Award (62500 shares) on 2025-07-16
Open Champions Oncology, Inc. (CSBR) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.